Cargando…

Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience

BACKGROUND: Recent UK clinical guidance advises against continuing trastuzumab (T) beyond disease progression (PD) in the absence of brain metastases in patients with HER-2 positive (+ve) advanced breast cancer .We have retrospectively evaluated the outcome of patients with HER-2+ve locally advanced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waddell, T, Kotsori, A, Constantinidou, A, Yousaf, N, Ashley, S, Parton, M, Allen, M, Starling, N, Papadopoulos, P, O'Brien, M, Smith, I, Johnston, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111155/ https://www.ncbi.nlm.nih.gov/pubmed/21522147 http://dx.doi.org/10.1038/bjc.2011.138

Ejemplares similares

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital
por: Cunningham, Niamh, et al.
Publicado: (2022)

Treatment of Epithelioid Sarcoma at the Royal Marsden Hospital
por: Livi, L., et al.
Publicado: (2003)

Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
por: Bamias, A., et al.
Publicado: (1995)

Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
por: Swerdlow, A. J., et al.
Publicado: (1997)

Dr. Marsden
Publicado: (1836)

Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience
por: Khan, Khurum, et al.
Publicado: (2015)

Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment.
por: Taylor, A. E., et al.
Publicado: (1995)

Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
por: Maruzzo, Marco, et al.
Publicado: (2015)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
por: Crawley, C., et al.
Publicado: (1998)

Dr. Marsden’s Plan of Quarantine
Publicado: (1866)

Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital
por: Thanopoulou, Eirini, et al.
Publicado: (2015)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

The practical aspects of propofol target controlled infusion for magnetic resonance imaging in children: An audit from the Royal Marsden Hospital
por: Haberman, Emily, et al.
Publicado: (2013)

Geometry, mechanics, and dynamics: the legacy of Jerry Marsden
por: Chang, Dong, et al.
Publicado: (2015)

The stretch reflex and the contributions of C David Marsden
por: Bhattacharyya, Kalyan B.
Publicado: (2017)

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
por: Arkenau, H-T, et al.
Publicado: (2008)

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience
por: Olmos, D, et al.
Publicado: (2008)

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
por: Tirelli, U
Publicado: (2008)

Student’s guide to calculus by J. Marsden and A. Weinstein
por: Soon, Frederick H
Publicado: (1985)

John Marsden's will: the Hornby estate case 1780–1840
por: Watson, Katherine D
Publicado: (2000)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2019)

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
por: Vathiotis, Ioannis A., et al.
Publicado: (2023)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

The Most Influential Scientist in the Development of Medical informatics (10): Marsden S. Blois
por: Masic, Izet
Publicado: (2016)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
por: Bianchini, Diletta, et al.
Publicado: (2017)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy
por: Gonzalez-Angulo, A M, et al.
Publicado: (2015)

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
por: Palle, Juliette, et al.
Publicado: (2017)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
por: Minuti, G, et al.
Publicado: (2012)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_088d0lc2lekior551p3tfvihjv